You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》兆科眼科(06622.HK)公开超购55倍及上限定价 一手中签率25%
阿思达克 04-28 09:32
由李氏大药厂(00950.HK)分拆的眼科制药公司兆科眼科-B(06622.HK)公布招股结果显示,计划发行约1.24亿股股份,原先当中10%於本港公开发售,本港公开发售录超购55倍,经重新分配後,公开发售股数增至40%。国际发售初步提呈发售股份已获相当於国际发售项下初步可供认购总数的约5.3倍以上。

每股上市发售价定於16.8元,为上限定价(招股价介乎15.38元至16.8元)

一手500股,中签率为25%。该股将於明日(29日)上市,高盛及Jefferies为联席保荐人。

兆科眼科为上市引入八名基石投资者,包括CaaS Capital、新加坡政府投资公司、奥博资本、Golden Valley、Jennison、Mass Ave、VMS Investment、Matthews International Capital Management,合共认购2,546.1万股股份,相当於公司紧随全球发售完成後已发行股份总数约4.76%。

公司预计集资净额为19.42亿元,当中约32%用於集团由25种候选药物组成的庞大管线中两种核心产品的临床开发及商业化;46%用於为其他在研候选药物的持续研发活动及商业化提供资金;7%用於南沙的先进生产设施进行生产线扩张;5%用於为业务开发活动及在研药物的扩展提供资金;余下10%将用作营运资金及其他一般企业用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account